Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5665_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
11 Мб
Скачать
☆
 
https://t.me/medicina_free
366
One TaqMan probe is designed to quantify the total number of alleles present in the sample (NHEJ insensitive reference probe, indicated as “Ref” on Figure14.5C) and another TaqMan probe is designed to quantify the number of edited alleles (NHEJ sensitive probe, indicated as “NHEJ” on Figure14.5C). Due to the impre­cise nature of NHEJ, edited sites contain indels of diverse sequence and therefore, it is not feasible to design a probe that can efficiently bind all possible sequences at the edited site. Instead, the “drop out” probe strategy is employed where the NHEJ sensitive probe is specific to the wild‐type version of the modification site and only produces fluorescent signal if DNA is not modified. Therefore, the num­ber of edited alleles is derived from the lack of signal from the NHEJ sensitive probe. The data are presented as a two‐dimensional plot where the wild‐type DNA signal is derived from NHEJ insensitive/NHEJ sensitive double positive droplets and the edited DNA signal is derived from the droplets with a decrease or loss of the signal from the NHEJ sensitive probe and positive signal from the NHEJ insensitive probe.
This ddPCR method was shown to be highly sensitive with a limit of detection (LOD) of 0.2–0.5% indels[69, 70]. The detention of indel frequency was also accu­rate when compared with NGS and flow cytometry with reported differences in as low as 4%[68]. To achieve such high analytical performance, the assay needs to be carefully optimized. This includes fine tuning of PCR conditions and determining probe sequences that provide the highest possible signal/noise ratio. Ideally, the edited site should be sequenced so that the NHEJ sensitive probe is designed accordingly[71]. Miyaoka etal. extended this assay to simultaneously quantify both HDR‐mediated point mutation correction and NHEJ‐mediated insertions and deletions[72, 73].
Due to the limit of the droplet number employed by the ddPCR platform (total 20,000 droplets), the gDNA amount used in the experiments should be carefully titrated to provide the appropriate resolution between NHEJ‐insensitive and NHEJ‐sensitive probes. High amounts of gDNA are not recommended as it may result in decreased assay sensitivity[70].
In summary, ddPCR can be a useful tool for quantification of NHEJ‐derived indels as well as HDR‐mediated point mutations and is characterized to have high sensitivity and a quick turnaround time (one day). It can be a cost‐effective option to monitor genome editing when the precise sequence information of the edits is not required.
14.3.3.2 Endonuclease Mismatch Cleavage Assays
Enzymatic detection of DNA mutations has been possible since the discovery of proteins, such as CEL‐I nuclease, which can cleave ssDNA present in mismatched regions of dsDNA [74]. Since its development by Sangamo Therapeutics in the mid‐to‐late 2000s [75], EMC has become one of the most commonly used
         367
https://t.me/medicina_free
methods to detect indels introduced by engineered nucleases. EMC uses mismatch‐ leave DNA homoduplexes intact [76] (Figure 14.5D). Firstly, gDNA is isolated from the edited sample and the genomic locus flanking the edited site is amplified using PCR. The PCR product is then denatured and reannealed resulting in DNA heteroduplexes containing mismatches where one DNA strand is wild‐type and another DNA strand contains an indel. This mixture is then treated with a nucle­ase that recognizes and cleaves the dsDNA at the site of mismatch. Lastly, the products of this reaction are resolved using methods such as gel electrophoresis. The approximate indel frequency is then estimated by quantifying the cleaved and intact DNA as represented by bands of different mobility (Figure14.5D). Optimal conditions for heteroduplex formulation between indel‐bearing and wild‐type DNA strands occurs when indel levels are relatively low (around 10%) and wild‐ type amplicons are in excess. Therefore, a simple formula can be applied to quan­tify percent modification (percent modification=fraction of cleaved bands/2). Once modification levels are higher, the formula needs to be corrected to account for the fact that indel‐bearing strands do not exclusively anneal with wild‐type strands[77]. There are several commercially available endonucleases that can be used for the EMC assay–Surveyor™ nuclease[78], T7 endonuclease I[76], CEL‐I endonuclease[79], T4 endonuclease VII[80], and endonuclease V[81]. The endo­nuclease should be carefully selected to suit the application as each enzyme has it is own properties that can impact the sensitivity, efficiency, and specificity of the EMC assay. The method used to separate the products of the cutting reaction can also impact the assay’s performance. For example, up to 3% editing can be detected using Surveyor™ nuclease and WAVE HSD HPLC[78] while up to 0.5% editing can be detected using T7 endonuclease I and gel electrophoresis in polyacryla­mide gel[82].
EMC has several limitations: false‐positive signals can be detected if the ana­lyzed genomic locus contains a single nucleotide polymorphism (SNP) that results in heteroduplex formation and enzymatic cleavage in unedited sample. Therefore, each investigated locus is tested for the absence of cutting using gDNA isolated from the naive sample. The EMC assay is also known to underestimate the editing efficiency due to the insensitivity of endonucleases to cleave heteroduplexes con­taining single base indel events–common editing outcomes for CRISPR/Cas9‐ based genome editing[83]. In addition, this assay is unsuitable for detecting high modification rates as mentioned above and low complexity samples (clonal or close to clonal cell lines) because mutated amplicons are able to reanneal and be resistant to endonuclease[83].
In summary, the EMC assay is simple, cost‐effective, and has a fast turnaround time (one day). However, it has several limitations that have restricted its use to academic settings or the early stages of drug development.
detection nucleases that selectively cleave DNA heteroduplexes but
 
https://t.me/medicina_free
368
14.3.3.3 Sanger Sequencing Combined withSequence Trace Decomposition
There are several methods for indel quantification that rely on low‐throughput sequencing. The targeted region together with the flanking DNA sequence can be amplified using PCR followed by Sanger sequencing. The PCR product can be either sequenced directly or first subcloned and then sequenced. Subcloning includes PCR product ligation with a plasmid, bacterial culture transformation, and spreading over the agar plates. Agar plates with the colonies can be sent to a commercial sequencing provider that returns Sanger sequence traces that are usu­ally analyzed manually. Subcloning is usually performed to increase the quality of Sanger sequence traces as PCR products may contain components inhibiting the Sanger sequencing reaction. This procedure is straightforward but labor‐intensive and comparatively lengthy. It is not recommended for samples with a low level of indels or high complexity samples with various indels at the edited site because many colonies will need to be sequenced to gain an accurate picture of editing frequency. Therefore, the Sanger sequencing approach is usually selected for clonal indel sequencing.
Notwithstanding these limitations, Sanger sequence traces can be used to quan­tify CRISPR‐introduced indels in high‐complexity samples using the methods of Tracking of Indels by Decomposition (TIDE) or Inference of CRISPR Edits (ICE) analyses[84, 85] (Figure14.5E). In these assays, the region of interest is amplified by PCR from both edited and wild‐type samples. PCR products are then purified, quantified, and Sanger sequenced. High quality Sanger sequencing data are essential to ensure successful computational analysis, therefore PCR products are usually carefully purified from the components of the PCR reaction and primer dimers. The sequencing from both ends of the amplicon is recommended to increase confidence in results. The Sanger sequences traces and gRNA sequence are uploaded to the software, which then compares sequencing traces corresponding to the untreated sample (wild‐type sequences) with the mixture of sequencing traces obtained from the edited sample. The software then reports a bar graph showing indel size and frequency, including frequencies of individual indels with­out providing the exact sequence of identified indels. A head‐to‐head comparison between ICE and NGS showed a good agreement where reported indel frequen­cies were largely similar across a variety of edited sequences [84, 86]. Similar results were reported for comparing TIDE and NGS where TIDE identified the same main indel types (where the indel frequency was ≥5%) and showed a nega­tive bias of about 10–20% [83]. Both TIDE and ICE are reproducible, reporting nearly identical results in replicate experiments with a LOD of about 2.5%[86]. Some of the reported disadvantages of TIDE and ICE were poorer performance in detecting longer indels and decreased sensitivity for detecting indels in high‐ complexity samples. In addition, TIDE was shown to diverge from NGS data sub­stantially when performed on individual clones containing both insertions and
         369
https://t.me/medicina_free
deletions in the same clone[83]. TIDE and ICE software are designed specifically for CRISPR and do not allow analysis for indels introduced by other genome editors.
The main limitation of TIDE and ICE is that they do not provide the exact sequence of identified indels. Due to the simplicity and free accessibility of the software, TIDE and ICE methodologies were widely adopted in the academic CRISPR field and are currently used for high‐throughput screening; however, its quantitative limitations have prevented it from being adopted in therapeutic genome editing efforts nearing the clinic.
14.3.3.4 Indel Detection by Amplicon Analysis (IDAA)
Indel Detection by Amplicon Analysis (IDAA) takes advantage of the ability of capillary electrophoresis to resolve small size differences between PCR ampli­cons [87] (Figure 14.5F). The optimized PCR labeling workflow was able to achieve resolution down to a single base‐pair[88]. In IDAA, the region of interest containing the edited site is PCR amplified using three primers‐ two of which are standard gene‐specific primers and the third is a 5′ fluorescently‐labeled universal primer complementary to an overhang on the forward primer. PCR reaction is carried out using touchdown PCR conditions with optimized primers ratio to yield uniformly labeled PCR amplicons with high purity. The labeled amplicons are then resolved using standard capillary electrophoresis and peaks are called using standard capillary electrophoresis software (for detailed protocol please see Ref.[89]). IDAA showed superior performance compared to EMC–IDAA is more sensitive, provides information about indel size, able to detect indels in homozy­gous clones. IDAA showed similar results when compared to NGS with a reported sensitivity of 0.1–1%[89]. Similar to TIDE, IDAA miscalled indels in multiple clones containing both insertions and deletions[83]. In addition, IDAA was not always able to call −1 and +1 nt peaks from the wild‐type peak, but it was possible to do by manual inspections of the peaks[83]. This technique can be a cost‐effective alternative to NGS when the exact sequence of the indels is not required.
In summary, NGS‐based methods became gold standard techniques for indel detection. NGS provides the frequency and exact sequence of indels with high sensitivity. Exact indel sequences may be required when evaluating the formation of clonality in cell therapy products. Due to the high cost of NGS and long turna­round time other methods can be advantageous. These methods can be applied when exact information about indel sequence is not required.
14.3.4 Technologies toMeasure Large Genomic Rearrangements
In addition to unintended editing resulting in indels at off‐target sites, larger genomic rearrangements such as large chromosomal deletions, inversions, and translocations have been detected at on‐ and off‐target sites[12] regardless of
 
https://t.me/medicina_free
370
engineered nucleases type[11, 90]. Translocations can occur when two or more DSBs are present on the same or two different chromosomes. In this case, one DSB is introduced intentionally by an engineered nuclease acting at a therapeutic site while another DSB is ectopic and introduced due to off‐target activities. Translocations were also detected with only one DSB at the on‐target location when the target region contained substantial sequence homology to another region located elsewhere in the genome[11, 12]. Large chromosomal deletions, inversions, and chromothripsis were also detected at the intended editing sites[11, 12, 14, 91]. Several studies showed that such mutations at the intended editing site may lead to detrimental effects in mitotically active cells[11, 14].
While to date large genomic rearrangements have only been observed in pre­clinical invitro experiments, the potential impact of such events during therapeu­tic editing compels us to understand their genesis in greater detail and develop technologies for their monitoring (Table14.2). There are several techniques used for genotoxicity assessment of edited cell therapy products. Historically, karyotyp­ing analysis using G‐banded chromosome analysis has been used to evaluate
Table14.2 Technologies tomeasure large genomic rearrangements.
Assay group Technologies Sensitivity Advantage Disadvantage Note
Cytogenetic Karyotype
Genome‐ wide molecular assays
Targeted molecular assays
Microscopy (G‐banded chromosome analysis), FISH
Targeted NGS
qPCR, ddPCR
Low GLP methods
available, cost‐effective, well established
High Provides
exact sequence at translocation site
High Relatively
easy to set up, cost‐effective
Low Sensitivity Gold standard
Complexity, require knowledge of one of the translocation partners, likely difficult to outsource
Need to know the exact sequence at rearrangement site
method
Useful at the discovery stage
Confirmation and quantification of rearrangements discovered by genome‐wide molecular assays
         371
https://t.me/medicina_free
potential structural and numerical chromosome aberrations following genome editing. Newer techniques incorporate fluorescence in situ hybridization (FISH) to identify and evaluate chromosomal rearrangements. Additionally, a soft agar transformation assay using human fibroblasts has been used to assess potential tumorigenicity risk of edited cells[92]. Karyotyping provides a high‐level view of chromosome aberrations, it has a fast turnaround time and is cost‐effective. Though karyotyping is still widely used in industry, it has low sensitivity due to limited resolution and the low number of events that can be screened in one sample.
Recently, NGS‐based techniques have been developed to identify large rear­rangements with sensitivity and specificity superior to karyotyping assays[93]. These techniques include anchored multiplex PCR sequencing (AMP‐seq)[93], linear amplification mediated high‐throughput genomic translocations sequenc­ing (LAM‐HTGTS)[40], uni‐directional targeted sequencing (UDiTaS)[94], and chromosomal aberrations analysis by single targeted linker‐mediated PCR sequencing (CAST‐seq) [40]. These methods are designed to identify chromo­somal aberrations involving on‐ and off‐target sites with prior knowledge of at least one fusion partner.
AMP‐seq was designed to assess single nucleotide variants, insertions, dele­tions, copy number changes, and translocations in clinical molecular diagnostic assays. It was then adopted by the genome editing community to analyze large rearrangements in samples treated with engineered nucleases. This method can detect fusion transcripts from RNA input or translocation using gDNA. Double‐ stranded cDNA or fragmented gDNA are end‐repaired, adenylated, and ligated with a half‐functional adapter that contains sample‐specific barcode. This step results in all DNA having the same 5′‐ and 3′‐ends. Purified products are then PCR amplified with a target‐specific primer and a primer complementary to a por­tion of the universal ligated adapter. This enables enrichment of target sequences where only one part of the sequence is known. The following nested PCR reaction accomplishes target enrichment and the addition of sequences fully functional for Ion Torrent or Illumina sequencing. Authors note that RNA‐based detection provides potentially easier unique alignment, deeper coverage, and information about expressed fusion transcript sequence. However, RNA‐based detection will miss transcriptionally unactive translocation detection. AMP‐seq is amenable to fresh and formalin‐fixed paraffin‐embedded (FFPE) material.
LAM‐HTGTS[40] is based on linear amplification PCR (LAM‐PCR), which is used for characterizing unknown DNA adjacent to known DNA. In LAM‐PCR primer is designed to bind known DNA sequence and produce multiple copies of known DNA linked to unknown DNA sequence in unidirectional manner. gDNA is first fragmented, then a biotinylated primer is designed to bind known sequences in a translocation event and generate multiple copies of the translocation
 
https://t.me/medicina_free
372
junction. The 5′‐biotinylated copy is then captured on streptavidin magnetic beads, ligated with bridge adapters followed by two rounds of nested PCR with adaptor and locus‐specific primers that add sample‐specific barcodes and sequences necessary for Illumina sequencing. After the first PCR step, a restric­tion enzyme is used to reduce the background from unrearranged targetalleles. Final libraries are sequenced using Illumina’s MiSeq platform. A bioinformatic pipeline then identifies and maps translocation junctions. This method is designed to detect off‐target editing and unbalanced chromosomal aberrations and meas­ure their relative frequencies. Yin etal. modified LAM‐HTGTS by decreasing number of linear amplification cycles from 80 to 1, introducing ligation with 14‐base pair random UMIs labeling each target copy, deeper sequencing with HiSeq, and improving bioinformatic analysis. This method was named primer‐ extension‐mediated sequencing (PEM‐seq)[95, 96]. The introduction of molecu­lar barcodes allowed to distinguish PCR duplicates from the original templates and together with improved bioinformatics analysis increased the assay sensitiv­ity. PEM‐seq can be applied for measuring short indels. The high amount of gDNA (20–100
μg) required for LAM‐HTGTS or PEM‐seq makes them more suitable
when testing material can be generated in large quantities.
UDiTaS[94] was developed for simultaneous measurement of small indels and larger structural rearrangements, such as large deletions, inversions, and translo­cations. This approach employs “tagmentation” where a custom‐designed Tn5 transposon is used to simultaneously shear gDNA and add universal priming sites to each fragmented DNA. After two rounds of PCR that enriches the target region and adds sample‐specific and Illumina barcodes, libraries are sequences on Illumina instruments. Using engineered cell lines and plasmid constructs with known indels and large rearrangements, the authors showed that this assay was able to measure down to 0.1% indel, large deletion and inversion events (≈1.1 base), and had 0.01% LOD for balanced, acentric, and dicentric fusions between homologous or unrelated chromosomes. Head‐to‐head comparison of UDiTaS and AMP‐seq was performed using plasmid surrogates mimicking a wild‐type locus, a large deletion, and inversion spiked into mouse gDNA (mouse matrix). The data showed high agreement between these two methods, both being linear between 2200 and 714,000 genome equivalents. UDiTaS requires 50 ng of gDNA to carry out the reaction and authors noted that assay sensitivity can be increased by increasing gDNA input and sequencing depth. The impact of increased gDNA input on “tagmentation” efficiency was not discussed but needs to be considered when developing this assay. Authors underlined the importance of carefully assessing this assay for each locus using plasmid DNA or engineered cell lines due to the potential sequence bias in tagmentation efficiency.
For CAST‐seq[11], gDNA is fragmented followed by linker ligation, in a similar fashion to AMP‐seq, followed by three PCR reactions. The first PCR reaction is
kilo-
         373
https://t.me/medicina_free
performed with a primer that binds to the on‐target sequence, a primer that rec­ognizes ligated linker sequence and “decoy primers” that bind the on‐target sequence to prevent amplification from targetalleles that are not involved in rear­rangements. The first PCR reaction will only result in a product if the binding sites of the decoy primers were lost due to a large rearrangement such as a trans­location or large deletions. The second and third PCR reactions introduce adapt­ers and barcode sequences necessary for NGS. The inclusion of “decoy primers” reduced background and increased the sensitivity of the assay by five‐fold. The number of translocation events in the sample is calculated by bioinformatic anal­ysis that takes into account that nuclease‐induced DSB can be processed differ­ently before translocation, each translocation having a distinct fusion point and linker ligation point. CAST‐seq requires 500 genomic rearrangements at a frequency of 0.006%.
Amit etal.[97] recently showed that translocations between on‐ and off‐target sites can be discovered from rhAmpSeq sequencing data using CRISPECTR soft­ware (please find detailed description of rhAmpSeq in “Amplicon sequencing” section). Because multiplexed PCR reaction contains primers targeting on‐ and off‐target sites, it will generate fusion PCR products originating from translocated alleles. Careful bioinformatic analysis can then report the translocation frequen­cies. More investigation needs to be done to understand the applicability of this approach to real biological samples. Special attention needs to be paid to unedited controls as PCR may generate fusion PCR products even without translocated DNA alleles.
Long‐range PCR with dual UMI approach [98] was applied for the detection and quantification of large insertions, deletions, and local chromosomal rear­rangements. Five‐ to 6‐kilobase genomic regions around edited site were ampli­fied and simultaneously tagged at 5′‐ and 3′‐ends with terminal UMIs using PCR reaction consisting of two cycles (UMI‐tagging PCR), followed by two consecutive PCR reactions to amplify UMI‐tagged molecules and add sample‐specific bar­codes for multiplexed sequencing. The resulting PCR product was subjected to SMRT‐seq library preparation and sequencing on PacBio sequencer. The assay was benchmarked using mixture of plasmids containing wild‐type sequence at 80% frequency and eight plasmids containing artificial long deletion ranging from 921 to 4416 bp at 20% frequency for all variants. The results showed high agree­ment between expected and experimental results, validating the utility of long‐ range sequencing for large deletions discovery and quantification. More in‐depth investigation is required to show the accuracy and precision of this assay for detecting indels, large insertions, and deletions of different length in the same sample.
All the techniques described above can be used for structural characterization and the discovery of large chromosomal rearrangements. Secondary techniques
ng of gDNA and is able to detect large
 
https://t.me/medicina_free
374
Table14.3 Comparison ofmolecular assays forgenome-wide assessment ofgenomic
rearrangements.
Reduction of
Methods Input
AMP‐seq Total RNA None Unknown Chromosomal rearrangements LAM‐
HTGTS PEM‐seq 20–50
UDiTaS 50
CAST‐seq 500
20–100 gDNA
μg
gDNA
ng gDNA None 0.01–0.1% Off‐target editing and
ng
gDNA
background Sensitivity Readout
μg
Restriction enzyme
None Unknown Off‐target editing and
Decoy primer 0.006% Chromosomal rearrangements
Unknown Off‐target editing and
chromosomal rearrangements
chromosomal rearrangements
chromosomal rearrangements
such as qPCR or ddPCR can then be used to quantify the frequency of structural variants once their genomic sequences are known[11].
Table14.3 provides overview of molecular assays for genome‐wide assessment of genomic rearrangements. There is currently no consensus in the genome edit­ing field on what technology should be used to monitor for large rearrangements. In addition, a specific study with benchmark samples is needed to assess and directly compare the currently available technologies (Figure14.6).
14.3.5 Discussion
On‐ and off‐target editing assessment is an essential part of pharmacology and safety evaluation during preclinical and clinical development of genome editing products. Because the target genomic site is known, the intended on‐target editing activity is typically measured by targeted sequencing analysis. The most widely used approach is target enrichment by PCR amplification (or hybrid capture) fol­lowed by NGS. For off‐target detection, early engagement with the health authori­ties is recommended to plan a series of studies to assess the safety and toxicity of untended editing activities. These studies include combining orthogonal in silico and invitro experimental analyses to perform genome‐wide off‐target site identifi­cation to determine a ranking list of potential off‐target sites, performing targeted sequencing to validate the sites in in vitro and/or invivo preclinical studies, and quantifying the editing events of validate sites in clinical trial samples to monitor the off‐target activities. Depending on the nuclease editing technology platform, the mechanism of action of the drug and the patient population, the appropriate unbiased and targeted methodologies with adequate assay sensitivities can be
         375
(a) (b) (c) (d)
https://t.me/medicina_free
AMP-seq
ds cDNA or
fragmented gDNA
End repair, dA tailing,
adaptor ligation
GSP PCR 1&2, SPRI
cleanup
lllumina sequencing
LAM-HTGTS and
PEM-seq
LAM-PCR
Enrichment on
Streptavidin beds and
bridge adapter ligation
Barcode PCR
Wt allele digest, PCR to
add lllumina adapters,
gel purication
lllumina sequencing
UDiTaS
Tagmentation, cleanup
GSP PCR, SPRI
cleanup
PCR to add l7
adaptor, SPRI cleanup
Size selection through gel
purication and Illumina
sequencing
CAST-seq
Fragmented gDNA
End repair, dA tailing,
adaptor ligation
PCR with “decoy” primer
GSP PCR, cleanup
PCR to add barcodes and
lllumina adapter, sequencing
Figure14.6 Technologies to measure large genomic rearrangements. (a) AMP-seq. Workflow
compatible with Illumina sequencing indicated. Two PCR step where universal forward primer and gene-specific primer (GSP) are used shown as one step where GSP2 is indicated. (b) LAM-HTGTS
workflow is shown. PEM-seq is different from LAM-HTGTS in number of linear amplification cycles,
introduction of 14-base pair random UMIs labeling each target copy, sequencing depth, and bioinformatic analysis. (c) UDiTaS. An example of method usage for translocation detection is shown. (d) CAST-seq. AMP-seq, LAM-HTGTS and CAST-seq start with DNA fragmentation using sonication which is not shown. TP–translocation partner, GSP–gene-specific primer, SPRI–Solid-phase reversible immobilization, LAM-PCR–linear-amplification–mediated PCR, pale gray indicates background gDNA. Source: Created with BioRender.com.
successfully designed to support regulatory filing and clinical development [92, 99]. For example, unbiased methods such as GUIDE‐Seq and related methodologies utilizing double‐stranded oligonucleotide capture have broad applications, among other methods, to identify potential off‐target sites of CRISPR, ZFN, and TALEN genome editing platforms. In addition to off‐target profiling, large genomic rear­rangements such as chromosomal translocation between on‐ and off‐target sites